ClinicalTrials.gg
TerminatedNCT05879822Updated Oct 20, 2026

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

A Phase 2 interventional study of INCB099280 in Advanced Solid Tumor, sponsored by Incyte Corporation. Terminated at 54 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Primary conditionnone(registry's first term: Carcinoma, Hepatocellular)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Carcinoma, Hepatocellular, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
This was a strategic business decision. There were no safety concerns contributing to this decision.
Updated Oct 20, 2026Now TerminatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Advanced Solid Tumor
  • Hepatocellular Carcinoma
  • Cutaneous Melanoma
  • PD-L1-positive NSCLC
  • Non-small Cell Lung Cancer
  • Renal Cell Carcinoma
  • Urothelial Cancer
  • MSI-H/dMMR Tumors
03

In context

Lead sponsor

Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.

Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Immunotherapy naive and without access to approved and/or available (ICI) therapy.
  • per v1.1.
  • One of the following disease settings:

    • Unresectable or Class A hepatocellular carcinoma (HCC) not eligible for surgical and/or locoregional therapy and have not received prior systemic therapy or had disease progression following primary therapy.
    • Unresectable or metastatic cutaneous melanoma and have not received more than 1 previous systemic therapy for advanced disease.
    • Unresectable Stage III PD-L1-positive (TPS ≥ 50% using the Dako PD-L1 IHC 22C3 assay) non-small cell lung cancer (NSCLC) without actionable molecular biomarkers and have not received prior systemic therapy and where chemoradiation is ; in addition, able to provide fresh or for central confirmation of PD-L1 expression.
    • Stage IV PD-L1-positive (TPS ≥ 50% using the Dako PD-L1 IHC 22C3 assay) NSCLC without actionable molecular biomarkers and have not received prior systemic therapy; in addition, able to provide fresh or archival tumor tissue for central confirmation of PD-L1 expression.
    • or Stage IV clear cell renal cell carcinoma (RCC) after having received 1 prior systemic therapy for relapsed or Stage IV disease.
    • Cisplatin-ineligible, locally advanced or Stage IV urothelial cancer (UC) and have not received prior systemic therapy for locally advanced or Stage IV UC and able to provide fresh or archival tumor tissue for central confirmation of PD-L1 expression using the Dako PD-L1 IHC 22C3 assay.
    • Advanced or metastatic microsatellite instability high (MSI-H) or deficient mismatch repair (dMMR) (as determined by an approved assay) solid tumors and able to provide fresh or archival tumor tissue for central confirmation of MSI-H or dMMR.
  • (ECOG) performance status score of 0 or 1.
  • > 3 months.
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

Exclusion Criteria:

  • Known history of an additional .
  • Central nervous system (CNS) requiring treatment and/or .
  • Toxicity from prior therapy that has not recovered.
  • Prior receipt of an , anti-PD-L1, or anti-PD-L2 agent or treatment with an immune modulator (eg, CTLA-4, GITR, LAG3, TIM3, OX40, ICOS, IL-2, 4-1BB, CAR-T cell).
  • Received thoracic radiation within 6 months of the first dose of study treatment.
  • Participation in another interventional clinical study while receiving INCB099280.
  • Impaired cardiac function or cardiac disease.
  • History or evidence of interstitial lung disease including noninfectious pneumonitis.
  • Presence of gastrointestinal conditions that may affect drug absorption.
  • Any disease requiring systemic treatment in the past 5 years.
  • Diagnosis of immunodeficiency or receiving chronic systemic therapy at a daily dose exceeding 10 mg of prednisone or equivalent.
  • Active infection requiring systemic therapy.
  • History of organ transplantation, including stem cell transplantation.
  • Receipt of systemic antibiotics within 28 days of first dose of study treatment.
  • Probiotic usage is prohibited during screening and throughout the study treatment period.
  • Received a within 28 days of the planned start of study drug.
  • Laboratory values outside the Protocol-defined ranges.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Part 1: INCB099280 Dose 1

    Participants will receive INCB099280 dose 1 twice daily (BID) for up to 2 years.

    Drug: INCB099280

  • Experimental
    Part 1: INCB099280 Dose 2

    Participants will receive INCB099280 dose 2 twice daily (BID) for up to 2 years.

    Drug: INCB099280

  • Experimental
    Part 1: INCB099280 Dose 3

    Participants will receive INCB099280 dose 3 twice daily (BID) for up to 2 years

    Drug: INCB099280

  • Experimental
    Part 2: INCB099280 Dose selected from Part 1

    Participants will receive INCB099280 dose selected from Part 1 twice daily (BID) for up to 2 years.

    Drug: INCB099280

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR), as determined by investigator radiographic disease assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: Up to 2 years

  2. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Defined as any Adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug up to 90 days after the last dose of study drug or until the start of new anticancer therapy, whichever occurs first.

    Time frame: Up to 2 years 3 months

  3. Number of participants with TEAEs leading to dose modification or discontinuation

    Number of participants with TEAEs leading to dose modification or discontinuation.

    Time frame: Up to 2 years

Secondary outcomes

  1. Disease Control Rate (DCR)

    Defined as the percentage of participants with the best overall response of CR or PR, or stable disease (SD), after a minimum of 15 weeks following the initiation of study treatment by investigator assessment per RECIST v1.1.

    Time frame: Up to 2 years

  2. Duration Of Response (DOR)

    Defined as the time from the earliest date of CR or PR until the earliest date of disease progression, as determined by investigator radiographic disease assessment according to RECIST v1.1, or death due to any cause if occurring sooner than progression.

    Time frame: Up to 2 years

  3. INCB099280 pharmacokinetic (PK) in Plasma

    INCB099280 concentration in plasma

    Time frame: Pre dose and 1, 2 and 6 hours post dose on Cycle 1 Day 1 and Cycle 2 Day 1. Pre dose every other cycle until Cycle 11 Day 1 (Cycle 3 Day 1, Cycle 5 Day 1, Cycle 7 Day 1, Cycle 9 Day 1 and Cycle 11 Day 1) (each cycle is 28 days)

07

Study locations

54 sites
  • Fundacao Pio Xii Hospital de Cancer de Barretos
    Barretos, 14784-400, Brazil
  • Cionc-Centro Integrado de Oncologia de Curitiba
    Curitiba, 80810-050, Brazil
  • Hospital Erasto Gaertner - Liga Paranaense de Combate Ao Câncer
    Curitiba, 81520-060, Brazil
  • Oncosite - Centro de Pesquisa Clinica E Oncologia
    Ijuí, 98700-000, Brazil
  • Clinica de Neoplasias Litoral Ltda
    Itajaí, 88301-220, Brazil
  • Fundacao Doutor Amaral Carvalho
    Jaú, 17210-120, Brazil
  • Hospital de Cancer de Londrina
    Londrina, 86015-520, Brazil
  • Irmandade Da Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, 90020-090, Brazil
  • Hgb - Hospital Giovanni Battista - Mae de Deus Center
    Porto Alegre, 90110-270, Brazil
  • Hospital Ernesto Dornelles
    Porto Alegre, 90160-093, Brazil
  • Hospital Nossa Senhora Da Conceicao
    Porto Alegre, 91350-200, Brazil
  • Cepho - Centro de Estudos E Pesquisas de Hematologia E Oncologia
    Santo André, 09060-870, Brazil
  • A. C. Camargo Cancer Center
    São Paulo, 01509-900, Brazil
  • The People'S Hospital of Guangxi Zhuang Autonomous Region
    Nanning, 530021, China
  • High Technology Hospital Medcenter
    Batumi, 06004, Georgia
  • Jsc Evex Hospitals
    Kutaisi, 04600, Georgia
  • Caucasus Medical Centre Llc
    Tbilisi, 00000, Georgia
  • Archangel St. Michael Multi Profile Clinical Hospital
    Tbilisi, 00102, Georgia
  • Israel-Georgian Medical Research Clinic Helsicore
    Tbilisi, 00112, Georgia
  • Todua Clinic, Llc
    Tbilisi, 00112, Georgia
  • New Hospitals
    Tbilisi, 00114, Georgia
  • Tim-Tbilisi Institute of Medicine Ltd
    Tbilisi, 00141, Georgia
  • Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic, Llc
    Tbilisi, 00144, Georgia
  • Institute of Clinical Oncology Ltd
    Tbilisi, 00159, Georgia
  • Cancer Research Center Ltd
    Tbilisi, 00177, Georgia
  • Medulla Chemotherapy and Immunotherapy Clinic
    Tbilisi, 00186, Georgia
  • 251 Air Force General Hospital
    Athens, 115 25, Greece
  • University Hospital of West Attica - Attikon
    Athens, 12462, Greece
  • Euromedica General Clinic of Thessaloniki
    Thessaloniki, 54645, Greece
  • Semmelweis Egyetem
    Budapest, 01083, Hungary
  • Orszagos Onkologiai Intezet
    Budapest, 01122, Hungary
  • Dunedin Hospital
    Dunedin, 09016, New Zealand
  • Rotorua Hospital
    Rotorua, 03010, New Zealand
  • Centrul Medical Medicover Victoria
    Bucharest, 10626, Romania
  • Institutul Clinic Fundeni Clinica
    Bucharest, 22328, Romania
  • Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca
    Cluj-Napoca, 400015, Romania
  • Spitalul Clinic Militar de Urgenta Dr. Constantin Papilian Cluj-Napoca
    Cluj-Napoca, 400132, Romania
  • Medisprof
    Cluj-Napoca, 400641, Romania
  • Centrul de Oncologie Sf. Nectarie Craiova
    Craiova, 200347, Romania
  • Sc Radiotherapy Center Cluj Srl
    Floreşti, 407280, Romania
  • Institutul Regional de Oncologie Iasi
    Iași, 700483, Romania
  • S.C. Medical Center Gral Srl
    Ploieşti, 100337, Romania
  • S C Oncocenter Oncologie Medicala S R L
    Timișoara, 300166, Romania
  • Oncomed Srl
    Timișoara, 300239, Romania
  • Cape Town Oncology Trials (Pty) Ltd
    Cape Town, 07570, South Africa
  • Johese Clinical Research: Midstream
    Centurion, 01692, South Africa
  • Wits Clinical Research
    Johannesburg, 02193, South Africa
  • The Medical Oncology Centre of Rosebank
    Johannesburg, 02196, South Africa
  • Phoenix Pharma (Pty) Ltd
    Port Elizabeth, 06001, South Africa
  • Medical Park Seyhan Hospital
    Adana, 01140, Turkey (Türkiye)
  • Hacettepe University Medical Faculty
    Ankara, 06100, Turkey (Türkiye)
  • Trakya University Medical Faculty
    Edirne, 22030, Turkey (Türkiye)
  • Goztepe Prof. Dr. Suleyman Yalcin City Hospital
    Istanbul, 34093, Turkey (Türkiye)
  • Kocaeli Universitesi Tip Fakultesi
    Kocaeli, 41380, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Sep 2026, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2023
First posted
May 30, 2023
StartActual
Oct 30, 2023
Primary completionActual
Sep 30, 2026
CompletionActual
Sep 30, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated This was a strategic business decision. There were no safety concerns contributing to this decision.
changed Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Active, not recruiting→Terminated
    Why stopped This was a strategic business decision. There were no safety concerns contributing to this decision.
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05879822
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
May 30, 2023
Start date
Oct 30, 2023
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Oct 20, 2026

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PD-L1 Inhibitor INCB099280

Start the discussion